International Biotechnology Trust’s Dyne Therapeutics DYN Stock Holding History

International Biotechnology Trust’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$1.23M	Sell	137,751 -163,000	-54%	-$1.76M	0.41%	46
2023 Q2	$3.38M	Sell	300,751 -133,000	-31%	-$1.57M	1.03%	31
2023 Q1	$4.99M	Sell	433,751 -207,317	-32%	-$2.69M	1.39%	24
2022 Q4	$7.42M	Buy	641,068 +291,000	+83%	+$3.37M	2.29%	17
2022 Q3	$4.44M	Buy	350,068 +346,203	+8,957%	+$3.97M	1.42%	24
2022 Q2	$563K	Sell	3,865 -472,135	-99%	-$3.25M	5.87%	3
2022 Q1	$1.16M	Hold	476,000	–	–	0.26%	52
2021 Q4	$5.64M	Buy	476,000 +226,000	+90%	+$3.18M	1.26%	26
2021 Q3	$4.06M	Buy	250,000 +115,000	+85%	+$2.04M	0.98%	30
2021 Q2	$2.84M	Buy	135,000 +41,114	+44%	+$773K	0.75%	31
2021 Q1	$1.45M	Buy	+93,886	New	+$1.82M	0.38%	40

Other funds holding DYN

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

International Biotechnology Trust's DYN Position: Q3 2023 in Review

International Biotechnology Trust reduced its Dyne Therapeutics (DYN) stake by 54% in Q3 2023, selling an estimated $1.76M and leaving 137,751 shares worth $1.23M. The position accounts for 0.41% of the portfolio, ranked #46.

International Biotechnology Trust first reported a position in DYN in Q1 2021 and has held it in 11 quarters since. The position peaked at $7.42M in Q4 2022. 114 funds tracked by Wall St. Rank hold DYN as of Q3 2023.

International Biotechnology Trust held 137,751 shares of Dyne Therapeutics worth $1.23M as of Q3 2023.
International Biotechnology Trust sold 163,000 Dyne Therapeutics shares in Q3 2023, an estimated $1.76M.
Dyne Therapeutics made up 0.41% of International Biotechnology Trust's portfolio in Q3 2023, its #46 holding.
International Biotechnology Trust first reported a position in Dyne Therapeutics in Q1 2021 and has held it in 11 quarters since.
International Biotechnology Trust's Dyne Therapeutics position peaked at $7.42M in Q4 2022.
114 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.